The use of buprenorphine in the treatment of chronic pain in the pain clinic

被引:0
|
作者
Jakubow, Piotr [1 ,2 ,3 ]
Kosel, Dariusz [2 ,3 ]
Kosciuczyk, Urszula [2 ,3 ]
Jarocka, Malgorzata [3 ]
Kopczynska, Antonina [3 ]
Domalewska, Aneta [3 ,4 ]
Ejsmont, Anna [3 ,5 ]
机构
[1] Uniwersytet Med Bialymstoku, Zaklad Farmakol Klin, Sklodowskiej 24a, PL-15215 Bialystok, Poland
[2] Uniwersytet Med Bialymstoku, Klin Anestezjol & Intensywnej Terapii, Bialystok, Poland
[3] Poradnia Leczenia Bolu NZOZ Vitamed, Bialystok, Poland
[4] Hosp Stacjonarne Dom Opatrznosci Bozej Bialymstok, Bialystok, Poland
[5] Uniwersytet Med Bialymstoku, Klin Psychiat, Bialystok, Poland
来源
MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE | 2016年 / 8卷 / 02期
关键词
opioids; buprenorphine; noncancer pain;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: The increased use of opioids in the treatment of chronic non-cancer pain has been observed in recent years. Buprenorphine is an opioid analgesic with an established position in pain therapy. Due to the unique pharmacological profile it is attractive to use in the outpatient clinic. The big advantage of the drug is the lack of tolerance induced by opioids and, theoretically, a high safety profile. The aim of the study is to analyse the use and safety profile of buprenorphine in patients with chronic nonmalignant pain at the Outpatient Pain Treatment Clinic. Material and methods: The records of patients treated at the Outpatient Pain Treatment Clinic were subjected to a retrospective analysis, as it was reported to the National Health Fund. Results: Buprenorphine was used in 9% of patients and it represented more than 50% in the group of opioid drugs. The largest group of patients consisted of those with the back pain in the lumbosacral segment. The most demanded choice was transdermal buprenorphine. There were no serious complications or critical side effects. For 3% of patients aged 65 years and more it was necessary to reduce the dose to improve the cognitive function. Due to the skin side effects it was also necessary to rotate the transdermal formulation. Conclusions: Buprenorphine, which is preferred as the treatment of choice in chronic non-malignant pain syndromes, is also effective and safe. The dose and form of the drug should be adjusted to the state and condition of the patient.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 50 条
  • [41] An Objective Pain Score for Chronic Pain Clinic Patients
    Pace, Agnes K.
    Bruceta, Melanio
    Donovan, John
    Vaida, Sonia J.
    Eckert, Jill M.
    PAIN RESEARCH & MANAGEMENT, 2021, 2021
  • [42] SUBLINGUAL BUPRENORPHINE FOR THE TREATMENT OF POSTOPERATIVE PAIN
    TOLKSDORF, W
    BANGERT, J
    GLOCKE, M
    MULLER, W
    ANASTHESIE INTENSIVTHERAPIE NOTFALLMEDIZIN, 1984, 19 (03): : 117 - 123
  • [43] Treatment of musculoskeletal pain with transdermal buprenorphine
    Ponce, A
    Aragon, A
    Neira, M
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 525 - 525
  • [44] Outcome of patients with chronic abdominal pain referred to chronic pain clinic
    McGarrity, TJ
    Peters, DJ
    Thompson, C
    McGarrity, SJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (07): : 1812 - 1816
  • [45] Treating Chronic Pain with Buprenorphine—The Practical Guide
    Amy A. Case
    Justin Kullgren
    Sidra Anwar
    Sandra Pedraza
    Mellar P. Davis
    Current Treatment Options in Oncology, 2021, 22
  • [46] Buprenorphine for Chronic Pain Management: a Narrative Review
    Vu, Peter D.
    Bansal, Vishal
    Chitneni, Ahish
    Robinson, Christopher L.
    Viswanath, Omar
    Urits, Ivan
    Kaye, Alan D.
    Nguyen, Anvinh
    Govindaraj, Ranganathan
    Chen, Grant H.
    Hasoon, Jamal
    CURRENT PAIN AND HEADACHE REPORTS, 2023, 27 (12) : 811 - 820
  • [47] Buprenorphine buccal film for chronic pain management
    Hale, Martin
    Gimbel, Joseph
    Rauck, Richard
    PAIN MANAGEMENT, 2020, 10 (04) : 213 - 223
  • [48] Buprenorphine Buccal Film (Belbuca) for Chronic Pain
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1492): : 47 - 48
  • [49] Buprenorphine for Chronic Pain Management: a Narrative Review
    Peter D. Vu
    Vishal Bansal
    Ahish Chitneni
    Christopher L. Robinson
    Omar Viswanath
    Ivan Urits
    Alan D. Kaye
    Anvinh Nguyen
    Ranganathan Govindaraj
    Grant H. Chen
    Jamal Hasoon
    Current Pain and Headache Reports, 2023, 27 : 811 - 820
  • [50] Treating Chronic Pain: Is Buprenorphine the (or Even an) Answer?
    Sun, Eric C.
    Mao, Jianren
    Anderson, T. Anthony
    ANESTHESIA AND ANALGESIA, 2018, 127 (02): : 336 - 337